News
Friday, August 22, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp.
1d
Zacks Investment Research on MSNPfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...
In the first half of 2025, Rinvoq generated sales of $3.7 billion, reflecting a 49% year-over-year increase. Rinvoq sales ...
Pfizer Inc faces a new challenge as Enanta Pharmaceuticals sues over a patent infringement concerning Paxlovid in the EU.
Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a ...
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 13596.29 with a total volume of 13,024.00. In the following chart, we are able to follow the development ...
Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...
Pfizer Inc. (PFE) recently updated investors on their ongoing Phase 3 clinical study, which could be a game-changer in lung ...
Alaska Communications owns and operates two submarine fiberoptic cales connecting Alaska with the contiguous United States: ...
Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on ...
Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results